PRT120
Peanut allergy
Phase 3Active
Key Facts
About Prota Therapeutics
Australian‑stage biotech delivering oral immunotherapy for peanut allergy with a Phase‑3 ready candidate.
View full company profileTherapeutic Areas
Other Peanut allergy Drugs
| Drug | Company | Phase |
|---|---|---|
| INP20 | InnoUp | Clinical |
| Food Allergy Program | Hal Allergy | Clinical Development |
| Peanut allergy program | Desentum | Unknown |
| Peanut Oral Immunotherapy | Camallergy | Phase 2 |
| INT301 (implied) | Intrommune Therapeutics | Pre-clinical |
| Ukko-Peanut | Ukko | Preclinical |
| VLP Peanut (VLP-p) | Allergy Therapeutics | Phase II |